ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone207-878-2770
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.99 million
Profitability
Miscellaneous
Employees47
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable
ImmuCell (NASDAQ:ICCC) Frequently Asked Questions
What is ImmuCell's stock symbol?
ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell's earnings last quarter?
ImmuCell Co. (NASDAQ:ICCC) announced its earnings results on Monday, August, 12th. The biotechnology company reported ($0.09) EPS for the quarter. The biotechnology company had revenue of $2.71 million for the quarter. ImmuCell had a negative return on equity of 7.35% and a negative net margin of 15.64%. View ImmuCell's Earnings History.
When is ImmuCell's next earnings date?
Has ImmuCell been receiving favorable news coverage?
Press coverage about ICCC stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ImmuCell earned a news impact score of 2.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for ImmuCell.
Are investors shorting ImmuCell?
ImmuCell saw a increase in short interest in October. As of October 31st, there was short interest totalling 4,500 shares, an increase of 80.0% from the September 30th total of 2,500 shares. Based on an average daily trading volume, of 6,900 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.1% of the shares of the company are sold short. View ImmuCell's Current Options Chain.
Who are some of ImmuCell's key competitors?
Some companies that are related to ImmuCell include Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), Akers Biosciences (AKER), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ).
What other stocks do shareholders of ImmuCell own?
Who are ImmuCell's key executives?
ImmuCell's management team includes the folowing people:
- Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
- Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
- Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
- Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)
How do I buy shares of ImmuCell?
Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ImmuCell's stock price today?
One share of ICCC stock can currently be purchased for approximately $4.90.
How big of a company is ImmuCell?
What is ImmuCell's official website?
How can I contact ImmuCell?
ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]
MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
